Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C25H34N4O5S.H3O4P |
| Molecular Weight | 600.621 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OP(O)(O)=O.COC1=CC(C)=C(C(C)=C1)S(=O)(=O)N(C)CCOCC(=O)N(C)CC2=CC=C(C=C2)C3=NCCN3
InChI
InChIKey=RMWOBELGMBYWEZ-UHFFFAOYSA-N
InChI=1S/C25H34N4O5S.H3O4P/c1-18-14-22(33-5)15-19(2)24(18)35(31,32)29(4)12-13-34-17-23(30)28(3)16-20-6-8-21(9-7-20)25-26-10-11-27-25;1-5(2,3)4/h6-9,14-15H,10-13,16-17H2,1-5H3,(H,26,27);(H3,1,2,3,4)
Safotibant (previously known as LF22-0542) was developed as an antagonist at bradykinin B1 receptor for the topical treatment of diabetic macular edema. This drug participated in phase II clinical trials in Australia, in Belgium and in the Czech Republic. However, further, development was discontinued.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
Y0VL627968
Created by
admin on Fri Dec 15 20:16:43 GMT 2023 , Edited by admin on Fri Dec 15 20:16:43 GMT 2023
|
PRIMARY | |||
|
1380572-99-5
Created by
admin on Fri Dec 15 20:16:43 GMT 2023 , Edited by admin on Fri Dec 15 20:16:43 GMT 2023
|
PRIMARY | |||
|
71587994
Created by
admin on Fri Dec 15 20:16:43 GMT 2023 , Edited by admin on Fri Dec 15 20:16:43 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
